stockrow
Friday 6 November 2026
Export GH’s income statement to Excel — free account
Guardant Health, Inc.
GH Healthcare Diagnostics & Research
Guardant Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $982.0 million, up 32.9% from fiscal 2024.
- Revenue
- +36.1%
- EPS
- −25.7%
- Free cash flow
- +18.7%
- Total debt
- +34.8%
Quarter to September 2026, against a year earlier
150.48
2.95
−1.92%
Follow GH
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 5 | 5 | 5 |
+8 more TTM periods Free account |
| 153.90% | 171.64% | 200.62% | 348.42% | ||
| (30.68%) | (27.95%) | (26.58%) | (23.79%) | ||
ROIC |
(25.68%) | (129.70%) | (127.36%) | (134.56%) | |
Return on Tangible Assets |
(43.24%) | (38.40%) | (35.35%) | (31.80%) | |
Average Days of Receivables |
53.24 | 44.50 | 46.43 | 51.24 | |
Free Cash Flow per Share |
(1.73) | (1.81) | (1.81) | (1.86) | |
Free Cash Flow |
(232.15) | (240.72) | (237.12) | (233.07) | |
Capital Expenditures |
(58.67) | (55.54) | (49.43) | (48.31) | |
| Other line items | |||||
Cash ROIC |
(18.93%) | (10.32%) | (9.78%) | (8.94%) | |
Accounts Receivable Turnover |
8.47 | 8.62 | 8.55 | 7.92 | |
Accounts Payable Turnover |
7.26 | 5.99 | 6.08 | 7.51 | |
Inventory Turnover |
4.84 | 4.37 | 4.71 | 4.45 | |
Average Days of Payables |
84.05 | 82.46 | 72.22 | 56.94 | |
Days of Inventory on Hand |
76.65 | 92.99 | 80.71 | 89.81 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
30.24% | 31.76% | 33.95% | 37.09% | |
Selling, General and Administrative Expense of Revenue |
74.37% | 73.00% | 72.38% | 71.90% | |
Share Based Compensation of Revenue |
16.50% | 16.17% | 16.30% | 16.93% | |
Interest Coverage |
(96.60) | (97.65) | (100.51) | (112.20) | |
Operating CF/Net income |
0.36 | 0.41 | 0.43 | 0.44 | |
Depreciation/Fixed assets |
0.00 | 0.16 | 0.18 | 0.23 | |
Capex/Depreciation |
0.00 | (2.19) | (1.84) | (1.43) | |
Revenue per Share |
9.51 | 8.90 | 8.23 | 7.83 | |
Operating CF per Share |
(1.29) | (1.39) | (1.43) | (1.47) | |
Capex per Share |
(0.44) | (0.42) | (0.38) | (0.39) | |
Capex to Sales |
0.05 | 0.05 | 0.05 | 0.05 |
Columns are period end dates · fundamentals updated 5 Nov 2026